Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Bacac

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Annual Review of Pathology|February 1, 2008
Metastatic cancer cellMarina Bacac, Ivan Stamenkovic
Oncoimmunology|September 14, 2016
CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumorsMarina Bacac, Christian Klein, Pablo Umana
Expert Opinion on Biological Therapy|January 11, 2023
Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS)Gabrielle Leclercq-Cohen, Marina Bacac, Christian Klein
Cancer Immunology, Immunotherapy : CII|June 29, 2004
Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cellsMarina Bacac, Marta Vadori, Gianni Sava, et al.
Expert Opinion on Investigational Drugs|August 29, 2017
Combination therapy with the type II anti-CD20 antibody obinutuzumabChristian Klein, Marina Bacac, Pablo Umana, et al.
The Journal of Antimicrobial Chemotherapy|September 3, 2002
Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic useSabrina Pacor, Anna Giangaspero, Marina Bacac, et al.
Frontiers in Immunology|May 7, 2025
Mechanistic insights into resistance mechanisms to T cell engagersLinlin Cao, Gabrielle Leclercq-Cohen, Christian Klein, et al.
Oncoimmunology|June 13, 2022
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitorsGabrielle Leclercq, Nathalie Steinhoff, Hélène Haegel, et al.
Plos One|December 22, 2006
A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survivalMarina Bacac, Paolo Provero, Nathalie Mayran, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2014
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicitySylvia Herter, Martina C Birk, Christian Klein, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Annual Review of Pathology|February 1, 2008
Metastatic cancer cellMarina Bacac, Ivan Stamenkovic
Oncoimmunology|September 14, 2016
CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumorsMarina Bacac, Christian Klein, Pablo Umana
Expert Opinion on Biological Therapy|January 11, 2023
Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS)Gabrielle Leclercq-Cohen, Marina Bacac, Christian Klein
Cancer Immunology, Immunotherapy : CII|June 29, 2004
Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cellsMarina Bacac, Marta Vadori, Gianni Sava, et al.
Expert Opinion on Investigational Drugs|August 29, 2017
Combination therapy with the type II anti-CD20 antibody obinutuzumabChristian Klein, Marina Bacac, Pablo Umana, et al.
The Journal of Antimicrobial Chemotherapy|September 3, 2002
Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic useSabrina Pacor, Anna Giangaspero, Marina Bacac, et al.
Frontiers in Immunology|May 7, 2025
Mechanistic insights into resistance mechanisms to T cell engagersLinlin Cao, Gabrielle Leclercq-Cohen, Christian Klein, et al.
Oncoimmunology|June 13, 2022
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitorsGabrielle Leclercq, Nathalie Steinhoff, Hélène Haegel, et al.
Plos One|December 22, 2006
A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survivalMarina Bacac, Paolo Provero, Nathalie Mayran, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2014
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicitySylvia Herter, Martina C Birk, Christian Klein, et al.
Pageof 8